AcquisitionsApr 27, 2026, 08:47 AM
BMRN Completes Amicus Therapeutics Acquisition for $4.8B
AI Summary
BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction at $14.50 per share. This strategic move strengthens BioMarin's commercial portfolio by adding Galafold® for Fabry disease and Pombiliti® + Opfolda® for Pompe disease, along with U.S. rights to DMX-200. The company also entered into a new credit agreement and expects to provide updated FY 2026 guidance during its first quarter earnings call on May 4, 2026.
Key Highlights
- Acquisition of Amicus Therapeutics completed.
- Total equity value of acquisition: approximately $4.8 billion.
- Acquisition price: $14.50 per share in an all-cash transaction.
- Adds Galafold® (Fabry disease) and Pombiliti® + Opfolda® (Pompe disease) to portfolio.
- Gains U.S. rights to DMX-200 for FSGS (Phase 3 development).
- Entered into a new credit agreement with Citibank, N.A. as Administrative Agent.
- Updated FY 2026 guidance expected during Q1 earnings call on May 4, 2026.